Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Adaptive Biotechnologies CorpADPT · Entity 1126 | Director | August 31, 2026 | September 02, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Adaptive Biotechnologies Corp
Report date August 31, 2026 · Filed September 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 66,100 |
Reported balance
After 2026-08-31 transaction · row 1
1 source rowRow 1 · 2026-08-31 · Gift · Disposed 12,539 · Balance 66,100 F1: Price is not applicable to dispositions resulting from bona fide gifts. |
Filing footnotes · ownership attribution and instrument terms
F1: Price is not applicable to dispositions resulting from bona fide gifts.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 31, 2026 Filed Sep 2, 2026 23:12 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | GiftCommon Stock | 12,539 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001852578-26-000007 · form4.xml · nonDerivative · entry 1 OWEN KATEY EINTERZ · CIK 0001852578 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 66,100 F1 · price: Price is not applicable to dispositions resulting from bona fide gifts. Read SEC document |
| August 26, 2026 Filed Aug 28, 2026 17:50 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 9,615 | $26.00 | $249,990.00 |
DisclosureSEC source: 0001852578-26-000005 · form4.xml · nonDerivative · entry 1 OWEN KATEY EINTERZ · CIK 0001852578 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 78,639 Read SEC document |
| March 04, 2026 Filed Mar 7, 2026 00:10 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | GrantCommon Stock | 15,625 | $0.00 | $0.00 |
DisclosureSEC source: 0001852578-26-000002 · form4.xml · nonDerivative · entry 1 OWEN KATEY EINTERZ · CIK 0001852578 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 88,254 Read SEC document |
| March 04, 2025 Filed Mar 7, 2025 00:16 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | GrantStock Option (right to buy) · Derivative | 23,726 | $0.00 Strike: $8.12 | $0.00 |
DisclosureSEC source: 0001062993-25-004806 · form4.xml · derivative · entry 2 OWEN KATEY EINTERZ · CIK 0001852578 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,726 Underlying: Common Stock · 23,726 shares Expires 2035-03-04 F1 · derivative.exercise_date: The option will vest in equal monthly installments over one year from March 4, 2025, subject to continued service as a director through such vesting dates. Read SEC document |
| March 04, 2025 Filed Mar 7, 2025 00:16 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | GrantCommon Stock | 15,394 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-25-004806 · form4.xml · nonDerivative · entry 1 OWEN KATEY EINTERZ · CIK 0001852578 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 72,629 Read SEC document |
| March 04, 2024 Filed Mar 7, 2024 00:45 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | GrantStock Option (right to buy) · Derivative | 48,044 | $0.00 Strike: $3.99 | $0.00 |
DisclosureSEC source: 0001062993-24-005774 · form4.xml · derivative · entry 2 OWEN KATEY EINTERZ · CIK 0001852578 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 48,044 Underlying: Common Stock · 48,044 shares Expires 2034-03-04 F1 · derivative.exercise_date: The option will vest in equal monthly installments over one year from March 4, 2024, subject to continued service as a director through such vesting dates. Read SEC document |
| March 04, 2024 Filed Mar 7, 2024 00:45 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | GrantCommon Stock | 31,328 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-24-005774 · form4.xml · nonDerivative · entry 1 OWEN KATEY EINTERZ · CIK 0001852578 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 57,235 Read SEC document |
| March 06, 2023 Filed Mar 9, 2023 01:08 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | GrantStock Option (right to buy) · Derivative | 23,329 | $0.00 Strike: $8.46 | $0.00 |
DisclosureSEC source: 0001062993-23-006336 · form4.xml · derivative · entry 2 OWEN KATEY EINTERZ · CIK 0001852578 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,329 Underlying: Common Stock · 23,329 shares Expires 2033-03-06 F1 · derivative.exercise_date: The option will vest in equal monthly installments over one year from March 4, 2023, subject to continued service as a director through such vesting dates. Read SEC document |
| March 06, 2023 Filed Mar 9, 2023 01:08 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | GrantCommon Stock | 14,775 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-006336 · form4.xml · nonDerivative · entry 1 OWEN KATEY EINTERZ · CIK 0001852578 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,907 Read SEC document |
| January 26, 2022 Filed Jan 29, 2022 00:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | GrantStock Option (Right to Buy) · Derivative | 16,722 | $0.00 Strike: $14.95 | $0.00 |
DisclosureSEC source: 0001209191-22-005494 · doc4.xml · derivative · entry 2 OWEN KATEY EINTERZ · CIK 0001852578 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,722 Underlying: Common Stock · 16,722 shares Expires 2032-01-26 F1 · derivative.exercise_date: The option will vest in equal monthly installments over one year, subject to continued service as a director through such vesting date. Read SEC document |
| January 26, 2022 Filed Jan 29, 2022 00:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | GrantCommon Stock | 6,689 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-005494 · doc4.xml · nonDerivative · entry 1 OWEN KATEY EINTERZ · CIK 0001852578 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,132 Read SEC document |
| March 17, 2021 Filed Mar 22, 2021 15:54 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | GrantStock Option (Right to Buy) · Derivative | 11,109 | $0.00 Strike: $45.01 | $0.00 |
DisclosureSEC source: 0001209191-21-022231 · doc4.xml · derivative · entry 2 OWEN KATEY EINTERZ · CIK 0001852578 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,109 Underlying: Common Stock · 11,109 shares Expires 2031-03-17 F1 · derivative.exercise_date: The options vest with respect to 1/4 of such shares on March 17, 2022, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. Read SEC document |
| March 17, 2021 Filed Mar 22, 2021 15:54 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | GrantCommon Stock | 4,443 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-022231 · doc4.xml · nonDerivative · entry 1 OWEN KATEY EINTERZ · CIK 0001852578 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,443 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.